| Literature DB >> 34229169 |
Tingting Ye1, Suying Guo2, Yang Xie3, Zhaoyue Chen4, Michael J Abramson5, Jane Heyworth6, Simon Hales7, Alistair Woodward8, Michelle Bell9, Yuming Guo10, Shanshan Li11.
Abstract
Due to the COVID-19 outbreak, the Chinese government implemented nationwide traffic restrictions and self-quarantine measures from January 23 to April 8 (in Wuhan), 2020. We estimated how these measures impacted ambient air pollution and the subsequent consequences on health and the health-related economy in 367 Chinese cities. A random forests modeling was used to predict the business-as-usual air pollution concentrations in 2020, after adjusting for the impact of long-term trend and weather conditions. We calculated changes in mortality attributable to reductions in air pollution in early 2020 and health-related economic benefits based on the value of statistical life (VSL). Compared with the business-as-usual scenario, we estimated 1239 (95% CI: 844-1578) PM2.5-related deaths were avoided, as were 2777 (95% CI: 1565-3995) PM10-related deaths, 1587 (95% CI: 98-3104) CO-related deaths, 4711 (95% CI: 3649-5781) NO2-related deaths, 215 (95% CI: 116-314) O3-related deaths, and 1088 (95% CI: 774-1421) SO2-related deaths. Based on the reduction in deaths, economic benefits for in PM2.5, PM10, CO, NO2, O3, and SO2 were 1.22, 2.60, 1.36, 4.05, 0.20, and 0.95 billion USD, respectively. Our findings demonstrate the substantial benefits in human health and health-related costs due to improved urban air quality during the COVID lockdown period in China in early 2020.Entities:
Keywords: Air pollution; COVID-19; China; Economic benefits; Health burden
Mesh:
Substances:
Year: 2021 PMID: 34229169 PMCID: PMC8241793 DOI: 10.1016/j.ecoenv.2021.112481
Source DB: PubMed Journal: Ecotoxicol Environ Saf ISSN: 0147-6513 Impact factor: 6.291
Percentage increase of all-cause mortality associated per specified unit increment of the air pollutant and its 95% confidence interval (CI).
| Air pollutant | Increase unit | Percentage increase (%) | 95% CI (%) | |
|---|---|---|---|---|
| Lower | Upper | |||
| PM2.5( | 10 µg/m3 | 0.22 | 0.15 | 0.28 |
| PM10( | 10 µg/m3 | 0.23 | 0.13 | 0.33 |
| Carbon monoxide( | 1 mg/m3 | 1.76 | 0.11 | 3.42 |
| Nitrogen dioxide( | 10 µg/m3 | 0.90 | 0.70 | 1.10 |
| Ozone( | 10 µg/m3 | 0.24 | 0.13 | 0.35 |
| Sulfur dioxide( | 10 µg/m3 | 0.59 | 0.42 | 0.77 |
Fig. 1Observed concentrations of the six criteria air pollutants in 367 Chinese cities during February and March from 2015 to 2020 (Please refer to Table A.1 for details).
Fig. 2Daily air pollution concentrations from February 1 to March 31 in 2020 (red line represents predicted business-as-usual concentrations and blue line represents observed concentrations) and 2015–2019 (average value in green line). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
The national (across 367 cities) reduced health burden (deaths) and associated economic benefits (value of statistical life) attributed to the change of six ambient air pollutants during COVID-19, compared to the business-as-usual scenario.
| Air pollutants | Reduced death counts (95% CI) | Value of statistical life in billion USD (95%CI) |
|---|---|---|
| CO | 1587 (98, 3104) | 1.36 (1.00, 2.26) |
| NO2 | 4711 (3649, 5781) | 4.05 (2.97, 6.75) |
| O3 | 215 (116, 314) | 0.20 (0.15, 0.34) |
| PM10 | 2777 (1565, 3995) | 2.60 (1.90, 4.33) |
| PM2.5 | 1239 (844, 1578) | 1.22 (0.90, 2.04) |
| SO2 | 1088 (774, 1421) | 0.95 (0.70, 1.58) |
Fig. 3The reduced health burden (death count) due to the decrease in concentrations of air pollutants in 367 cities during COVID-19, compared to the business-as-usual scenario.
Fig. 4Value of statistical life (unit: billion USD) saved due to avoided mortalities from decrease in air pollutants for February and March 2020 in 31 provinces during COVID-19, comparing to the business-as-usual scenario.
Fig. 5Values of statistical life (unit: billion USD) saved due to decrease in air pollutants in 367 cities during COVID-19.